TY - JOUR
T1 - Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.
AU - Di Marco, Vito
AU - Stroffolini, null
AU - Ferrari, Carlo
AU - Santantonio, Teresa
AU - Ancarani, Fausto
AU - Francavilla, null
AU - Cariti, Giuseppe
AU - Medda, null
AU - Babudieri, Sergio
AU - Scotto, Gaetano
AU - Toti, Mario
AU - Massari, Marco
AU - Fabris, null
AU - Antonucci, null
AU - Pastore, Giuseppe
PY - 2006
Y1 - 2006
N2 - Background. The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated.Methods. To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of months. Biochemical liver tests were performed, and HCV RNA levels 14 +/- 15.8 were monitored.Results. A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C.Conclusions. These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C-both symptomatic and asymptomatic-have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment
AB - Background. The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated.Methods. To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (+/- SD) period of months. Biochemical liver tests were performed, and HCV RNA levels 14 +/- 15.8 were monitored.Results. A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C.Conclusions. These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C-both symptomatic and asymptomatic-have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment
UR - http://hdl.handle.net/10447/12384
M3 - Article
SN - 1058-4838
VL - 43
SP - 1154
EP - 1159
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -